[HTML][HTML] ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
DW Lee, BD Santomasso, FL Locke, A Ghobadi… - Biology of blood and …, 2019 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most
promising therapies for hematologic malignancies. Two CAR T products were recently …
promising therapies for hematologic malignancies. Two CAR T products were recently …
Mouse models of graft-versus-host disease: advances and limitations
MA Schroeder, JF DiPersio - Disease models & …, 2011 - journals.biologists.com
The limiting factor for successful hematopoietic stem cell transplantation (HSCT) is graft-
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …
versus-host disease (GvHD), a post-transplant disorder that results from immune-mediated …
Cytokines and hematopoietic stem cell mobilization
B Nervi, DC Link, JF DiPersio - Journal of cellular biochemistry, 2006 - Wiley Online Library
Hematopoietic stem cell transplantation (HSCT) has become the standard of care for the
treatment of many hematologic malignancies, chemotherapy sensitive relapsed acute …
treatment of many hematologic malignancies, chemotherapy sensitive relapsed acute …
[HTML][HTML] Recurring mutations found by sequencing an acute myeloid leukemia genome
ER Mardis, L Ding, DJ Dooling… - … England Journal of …, 2009 - Mass Medical Soc
Background The full complement of DNA mutations that are responsible for the
pathogenesis of acute myeloid leukemia (AML) is not yet known. Methods We used …
pathogenesis of acute myeloid leukemia (AML) is not yet known. Methods We used …
[HTML][HTML] DNMT3A Mutations in Acute Myeloid Leukemia
Background The genetic alterations responsible for an adverse outcome in most patients
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …
with acute myeloid leukemia (AML) are unknown. Methods Using massively parallel DNA …
[HTML][HTML] Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Most patients with acute myeloid leukaemia (AML) die from progressive disease after
relapse, which is associated with clonal evolution at the cytogenetic level,. To determine the …
relapse, which is associated with clonal evolution at the cytogenetic level,. To determine the …
[HTML][HTML] The origin and evolution of mutations in acute myeloid leukemia
Most mutations in cancer genomes are thought to be acquired after the initiating event,
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …
which may cause genomic instability and drive clonal evolution. However, for acute myeloid …
[HTML][HTML] A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
S Verstovsek, RA Mesa, J Gotlib, RS Levy… - … England Journal of …, 2012 - Mass Medical Soc
Background Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically
significant activity in myelofibrosis. Methods In this double-blind trial, we randomly assigned …
significant activity in myelofibrosis. Methods In this double-blind trial, we randomly assigned …
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Several genetic alterations characteristic of leukemia and lymphoma have been detected in
the blood of individuals without apparent hematological malignancies. The Cancer Genome …
the blood of individuals without apparent hematological malignancies. The Cancer Genome …
[HTML][HTML] DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Acute myeloid leukaemia is a highly malignant haematopoietic tumour that affects about
13,000 adults in the United States each year. The treatment of this disease has changed …
13,000 adults in the United States each year. The treatment of this disease has changed …